<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><title></title></head><body><h1>HELICOBACTER PYLORI</h1>

<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467250/">reference</a></p>

<ul>
<li>maybe present in more than half of the world population</li>
<li>infects the stomach during childhood</li>
<li>communicalble through saliva, vomit or fecal matter</li>
<li>faculatative intracellular bacterium of innate immune cells capable of interfering with the phagosome maturation </li>
<li>risk for gastric ca, along with EBV</li>
</ul>

<h2>CLINICAL FEATURES</h2>

<ul>
<li><strong>asymptomatic gastritis</strong></li>
<li><strong>gastrointestinal malignancy</strong></li>
<li><strong>ulcers</strong>

<ul>
<li>dudoenal ulcers - 95% </li>
<li>gastric ulcers - 5%</li>
</ul></li>
</ul>

<blockquote>
<p>NOTE: 50% of gastric ulcers and 80% of duodenal ulcers are associated with infection and eradication reduces the risk of ulcer recurrence</p>
</blockquote>

<ul>
<li><p>infection -&gt; acute gastritis -&gt; hypochlorhydria -&gt; chronic active gastritis of antrum- 95%(inc acid secretion and duodenal ulcer), corpus- 5% (gastric atrophy and achlorhydria) or both (so hpylori can cause both inc and dec acid secretion)</p></li>
<li><p><strong>MALT</strong>(low grade b cell marginal zone lymphoma) - hpylori(75% association) - <a href="https://monographs.iarc.who.int/agents-classified-by-the-iarc/">group 1 carcinogen</a> - if detected early complete remission with antibacterial rx</p></li>
<li><p><strong>gastric adenocarcinoma</strong> - repeated gastritis - atrophy - intestinal metaplasia - dysplasia - carcinoma</p></li>
</ul>

<blockquote>
<p>NOTE: alarm signs of <a href="https://www.ncbi.nlm.nih.gov/books/NBK554563/">dyspepsia</a> (fam h/o proximal gastrointestinal cancer, gi bleed, odynophagia, progressive dysphagia, unexplained iron def anemia, unintentional wt loss, persistent vomiting, palpable mass, lymphadenopathy, jaundice)</p>
</blockquote>

<ul>
<li><p>20 to 60% of pts with <a href="https://www.ncbi.nlm.nih.gov/books/NBK554563/">functional dyspepsia</a> have hpylori infection - and eradication results in symptomatic benefit in 10% of these patients </p></li>
<li><p>pts &lt;55 who have new-onset dyspepsia without alarm features should undergo Hpylori testing and treatment</p></li>
<li><p><strong>hpylori reduced serum ferritin and iron levels in cad thus acting as an independent risk factor</strong> </p></li>
<li><p>also has a role in ITP, iron deficiency anemia, b12 deficiency, pre eclampsia</p></li>
</ul>

<h2>INVESTIGATION</h2>

<ul>
<li>UBT (urea breath test) - 10-20 mins after swallowing a capsule containing urea, a breath sample is collected and analyzed for labeled co2 - positive test signifies active infection - turns negative after eradication - so used to test eradication(ppi, antibiotic, bismuth reduce urea production so should be held before test)</li>
<li>endoscopy - test for inflammation and ulcers, biopsy can be taken for culture</li>
<li>stool sample - antibody test - can be used to test eradication</li>
</ul>

<p><img src="./hpylori_investigations.png" alt="investigation"></p>

<h2>TREATMENT</h2>

<ul>
<li>should be give to all pts with hpylori, malt lymphomas</li>
<li>capable of developing resistance so 2/more antibiotics used together with ppi and/or bismuth containing compounds.</li>
<li>pts who have already taken metro and clarythro/erythro have resistance for these antibiotics</li>
</ul>

<p><img src="./rx_hpylori.png" alt="rx drugs"></p>

<p><img src="./rx_algorithm.jpg" alt="rx algorith"></p>

<p><img src="./rx_failure_plan.jpg" alt="rx failure plan"></p>

<ul>
<li>confirm eradication with ubt/stool antigen test 4 weeks after completion of therapy</li>
</ul>

<p>triple therapy(ppi, amox, cla) -&gt; resistance to cla -&gt; switch to metro(ppi, amox, metro) -&gt; resistance to metro -&gt; quadruple therapy(ppi,bismuth,metro,tetra) -&gt; failure -&gt; sequential therapy(ppi, amox first 4 days, then ppi, cla/tinidazole for 5days) -&gt; failure -&gt; salvage therapy (ppi, amox, levo)</p>
</body></html>